CellCentric and ZoBio Enter into Partnership to Develop Lead Compounds Against Epigenetic Drug Targets
|| Print ||
|Wednesday, 20 June 2012 09:30 (UTC + 2)|
Leiden, NL and Cambridge, UK, June 20, 2012 / B3C newswire / - ZoBio and CellCentric are pleased to announce that the companies are working together to discover lead compounds against CellCentric’s portfolio of epigenetic therapeutic drug targets. ZoBio will use its proprietary TINS technology to screen its fragment library against targets nominated by CellCentric. Hit to lead and lead optimisation activities will be further supported by ZoBio’s biophysical and medicinal chemistry research services.
Dr. Gregg Siegal, Chief Scientific Officer at ZoBio said “We are clearly happy that CellCentric has chosen ZoBio as a partner in this challenging project. Epigenetics is an exciting, yet challenging, field. We feel that our unique combination of biophysical and biochemical approaches yields significant advantages in developing small molecule inhibitors of these targets with optimal drug-like properties.”
Dr Anthony Brown, Scientific Director at CellCentric, said “The ZoBio TINS technology offers a unique opportunity to identify novel hit matter against our epigenetic drug targets. The interaction with ZoBio will allow us to expand the breath of our hit finding capabilities and will accelerate our on-going drug discovery activities. We are delighted to enter into this agreement to screen against these novel and exciting epigenetic drug targets.”